Pittsburgh – October 12, 2026 -- STERIS, a roughly $6 billion-revenue infection prevention provider with 18,000 Associates, has agreed to acquire Pittsburgh-area surgical safety specialist Xodus Medical, adding a portfolio of operating room consumables.
Financial terms were not disclosed in the announcement.
STERIS Targets Double-Digit Growth in Specialty Surgical Products
STERIS President and CEO Dan Carestio said Xodus Medical's portfolio complements and expands the STERIS offering, particularly through consumables used in the operating room. He said the business has demonstrated an ability to grow at double-digit rates, supported by a specialty product portfolio, a steady stream of new products and a highly effective commercial team.
Carestio said the combined company aims to enhance service to customers and create value for STERIS shareholders.
Xodus Medical Brings 30-Year Surgical Safety Franchise
Xodus Medical was founded in 1993 and is headquartered near Pittsburgh, Pennsylvania. Its proprietary surgical safety technologies include the flagship Pink Pad® patient positioning systems, which serve hospitals worldwide.
Xodus CEO Craig Kaforey said the deal would let the company combine its products and expertise with STERIS's resources, industry knowledge and established market presence. He also pointed to growth opportunities for Xodus employees within a global organization.
Goldman Sachs and J.P. Morgan Lead Deal Advisory
Goldman Sachs & Co. LLC is exclusive financial advisor to STERIS, with Jones Day as legal counsel. J.P. Morgan is exclusive financial advisor to Xodus Medical, with Morgan, Lewis & Bockius LLP serving as legal counsel.
The announcement did not specify a closing timeline or conditions.